ACADIA Pharmaceuticals Inc (ACAD)

Sep 25, 2026

Acadia Pharmaceuticals (ACAD) saw its stock drop almost 7% on Friday, following a 13% decline the previous day. This downturn resulted from the company reporting topline Phase 2 results for its RADIANT study, where the drug remlifanserin narrowly missed its primary endpoint for Alzheimer's disease psychosis. Despite the setback, analysts note continued support from existing commercial products and ongoing Phase 3 development for remlifanserin.

Sep 25, 2026

Design firm Ware Malcomb announced the completion of construction for Acadia Pharmaceuticals Inc.'s 62,600-square-foot East Coast headquarters in Princeton. Ware Malcomb's Princeton office provided interior architecture and design services, focusing on Acadia's brand identity and workplace functionality. The two-level office includes executive spaces, meeting rooms, open work areas, and a dedicated conference center, designed with biophilic principles in mind.

Sep 25, 2026

Acadia Pharmaceuticals (NASDAQ: ACAD) stock dropped 19% today after its remlifanserin Phase 2 trial for Alzheimer's disease psychosis narrowly missed its primary endpoint. Despite the setback, management is proceeding with Phase 3 trials, emphasizing encouraging secondary measures and a favorable safety profile. Analysts have adjusted price targets but maintain "Outperform" or "Buy" ratings, with TIKR's valuation model suggesting a potential 54% upside to $34, contingent on continued success of existing drugs and clearer Phase 3 results for remlifanserin.

Sep 25, 2026

Acadia Pharmaceuticals' stock is down after its remlifanserin drug for Alzheimer's disease psychosis narrowly missed its primary goal in a Phase 2 trial, though it showed promise in a secondary endpoint and a favorable safety profile. The company plans to proceed with a Phase 3 study using a 60 mg dose. Technically, the stock faces bearish momentum, trading below key moving averages with an oversold RSI, despite an earlier "golden cross" signal.

Sep 24, 2026

Acadia Pharmaceuticals (NASDAQ: ACAD) stock fell 19% after its Alzheimer's drug, remlifanserin, narrowly missed its primary endpoint in a Phase 2 trial. Despite the setback, management is pushing forward with Phase 3 trials, supported by a favorable safety profile and strong secondary endpoint results. Analysts have adjusted price targets, with a valuation model suggesting a potential 54% upside to $34 per share based on continued growth of existing drugs DAYBUE and NUPLAZID and successful Phase 3 outcomes for remlifanserin.

Sep 24, 2026

ACADIA Pharmaceuticals saw its shares drop 10% pre-bell after its Remlifanserin study missed its main endpoint. The article also notes recent activities like the EU approval of their Rett Syndrome drug Daybu and various analyst adjustments to their price targets. The company is focused on neurological and rare disease communities with a pipeline that includes treatments for Alzheimer's disease psychosis and Lewy body dementia psychosis.

Sep 24, 2026

Acadia Pharmaceuticals' shares dropped 6% after its Phase 2 RADIANT study for remlifanserin in Alzheimer's disease psychosis missed its primary endpoint. Although the 60 mg dose showed nominal statistical significance on a key secondary endpoint (CGI-S-ADP), the primary SAPS H+D endpoint was not met. Despite these results, Acadia plans to continue with two ongoing Phase 3 studies, removing the 30 mg dose arm.